Lewis William, an insider at Insmed Inc (INSM), sold 303,911 shares of the company's stock on December 17, 2025, at a price of $171.20 per share. The total value of this transaction amounted to $52.03 million. Following this sale, William retains 303,911 shares in the company.
Insmed, a biotechnology firm based in Bridgewater, New Jersey, focuses on developing therapies for rare diseases. The company has a market capitalization of $35.8 billion and employs 1,271 full-time staff. Its advanced programs target pulmonary and inflammatory conditions, including its approved therapy for a chronic lung disease.
Insider selling can occur for various reasons, such as diversification or personal financial needs. While significant sales may attract attention, they do not inherently reflect negative sentiments about the company. Investors should consider insider transactions as one of many factors in their analysis, examining patterns across multiple insiders and time periods to gain a clearer picture.
Insmed's upcoming earnings report is scheduled for May 6, 2026, with an estimated EPS of -1.24 and revenue of $195.3 million, followed by another report on August 5, 2026, estimating an EPS of -1.07 and revenue of $255.3 million.